97179 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
Sub-classes:LONG ACTING ALPHA4BETA7 TARGETING MOLECULE COMPOSITIONS FOR THE TREATMENT GASTROINTESTINAL INFLAMMATORY DISEASE
#2HUMANIZED ANTIBODIES TO HUMAN INTEGRIN AVB8
#3CELL CULTURE COMPOSITIONS AND METHODS FOR POLYPEPTIDE PRODUCTION
#4COMPOSITIONS AND METHODS OF DELIVERING LARGE PROTEINS
#5STABLE LYOPHILIZED FORMULATION OF AN ANTI-alpha4beta7 ANTIBODY
#6ANTI-ALPHA-4-BETA-7 ANTIBODIES
#7ANTIBODY AND USE THEREOF
#8BINDING AGENTS AND USES THEREOF
#9METHODS FOR TREATING ENDOMETRIAL AND OVARIAN HYPERPROLIFERATIVE DISORDERS
#10LONG ACTING ALPHA4BETA7 TARGETING MOLECULE COMPOSITIONS FOR THE TREATMENT GASTROINTESTINAL INFLAMMATORY DISEASE
#11COMPOSITIONS FOR TARGETING MUSCLE CELLS AND USES THEREOF
#12NEW ANTI-ITGB8 ANTIBODIES AND ITS USES THEREOF
#13METHOD OF TREATING INFLAMMATORY BOWEL DISEASE
#14INJECTABLE FORMULATIONS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE
#15IMMUNOMODULATORY FUSION PROTEINS AND RELATED METHODS
#16PHARMACEUTICAL ASSOCIATION OF GROWTH FACTOR RECEPTOR AGONIST AND ADHESION PROTEIN INHIBITOR FOR CONVERTING A NEOPLASTIC CELL INTO A NON-NEOPLASTIC CELL AND USES THEREOF
#17ASSESSMENT OF INTESTINAL BARRIER FUNCTION TO IMPROVE TREATMENT OF INFLAMMATORY BOWEL DISEASE
#18ALPHA4BETA7 INTEGRIN BINDING PROTEINS AND METHODS OF USE
#19ANTI-INTEGRIN ANTIBODIES AND USES THEREOF
#20METHODS FOR TREATMENT USING ANTI-ALPHA4BETA7 ANTIBODY
#21METHODS FOR TREATMENT USING ANTI-ALPHA4BETA7 ANTIBODY
#22METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST
#23FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTIBODY THERAPEUTICS
#24PROCESS FOR PREPARING PURIFIED DRUG CONJUGATES
#25METHODS AND MATERIALS FOR TREATING GRAFT-VERSUS-HOST DISEASE
#26METHODS OF TREATING GASTROINTESTINAL INFLAMMATORY DISEASE
#27MULTI-COMPONENT BUFFER SYSTEM FOR PURIFICATION OF ANTIBODIES
#28ANTI-AVB6 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
#29ANTI-alpha-V-beta-8 INTEGRIN ANTIBODIES AND USES THEREOF
#30RETROVIRAL-LIKE PARTICLE-REDUCED CHINESE HAMSTER OVARY PRODUCTION CELL LINES
#31PHARMACEUTICAL COMPOSITION CONTAINING ANTI-INTEGRIN ALPHA11 ANTIBODY FOR TREATMENT OR PREVENTION OF AGING-RELATED DISEASES
#32METHODS OF TREATING OR PREVENTING GRAFT VERSUS HOST DISEASE
#33BTNL3/8 TARGETING CONSTRUCTS FOR DELIVERY OF PAYLOADS TO THE GASTROINTESTINAL SYSTEM
#34VEDOLIZUMAB FORMULATION
#35METHODS OF TREATING HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE
#36METHODS FOR TREATMENT USING ANTI-ALPHA4BETA7 ANTIBODY
#37FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY
#38METHODS AND PRODUCTS FOR EVALUATING AN IMMUNE RESPONSE TO A THERAPEUTIC PROTEIN
#39NEUTRALIZING ANTIBODIES TO THE ALPHA V BETA 8 INTEGRIN COMPLEX FOR IMMUNOTHERAPY
#40COMPOSITIONS AND METHODS OF ALLEVIATING RESISTANCE TO CHEMOTHERAPY
#41PREVENTION OF POSTERIOR CAPSULAR OPACIFICATION (PCO) WITH INTEGRIN AVB8 BLOCKING ANTIBODY
#42METHODS FOR TREATMENT USING ANTI-ALPHA4BETA7 ANTIBODY
#43COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH AVB8 INTEGRIN
#44Bispecific Binding Molecule
#45INHIBITORS FOR USE IN PREVENTION- AND/OR ALLEVIATION OF HEART FIBROSIS
#46METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES
#47METHOD TO OBTAIN A PURIFIED ANTIBODY COMPOSITION
#48Methods of Controlling the Formation of Disulfide Bonds in Protein Solutions
#49BIOMARKERS FOR ASSESSING THE RESPONSE STATUS FOR TREATMENT OF INFLAMMATORY CONDITION OR DISEASE AFFECTING THE DIGESTIVE TRACT SUCH AS INFLAMMATORY BOWEL DISEASE IN HUMAN PATIENTS
#50A PROCESS TO PRODUCE A PHARMACEUTICAL COMPOSITION
#51VEDOLIZUMAB FOR THE TREATMENT OF FISTULIZING CROHN'S DISEASE
#52Method To Control High Molecular Weight Aggregates In An Antibody Composition
#53ANTIBODY
#54TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNE MODULATORY AGENT RELEASED USING AN INGESTIBLE DEVICE
#55Liquid Protein Formulations Containing Ionic Liquids
#56Method To Purify An Antibody Composition Using Cation Exchange Chromatography
#57VEDOLIZUMAB FORMULATION
#58METHODS OF TREATING GASTROINTESTINAL IMMUNE-RELATED ADVERSE EVENTS IN IMMUNE ONCOLOGY TREATMENTS
#59A METHOD OF IMPROVING STABILITY OF AN ANTIBODY FORMULATION
#60METHODS FOR THE TREATMENT OF CHRONIC POUCHITIS
#61Liquid Protein Formulations Containing Viscosity-Lowering Agents
#62PREDICTING OUTCOME OF TREATMENT WITH AN ANTl-alpha4beta7 INTEGRIN ANTIBODY
#63TOPOLOGICALLY ENGINEERED SUPERDIMERIC ANTIBODIES
#64FREEZE DRIED ANTIBODY FORMULATIONS AND METHODS THEREOF
#65ANTI-VLA-4 ANTIBODIES
#66STABLE FORMULATION OF INTEGRIN ANTIBODY
#67METHODS AND COMPOSITIONS RELATING TO BISPECIFIC ANTI-CHI3L1 ANTIBODY REAGENTS
#68Anti-αVβ6 antibodies and antibody-drug conjugates
#69CELL CULTURE COMPOSITIONS AND METHODS FOR POLYPEPTIDE PRODUCTION
#70METHOD OF INHIBITING EXACERBATIONS OF T CELL-MEDIATED ALLOGRAFT VASCULOPATHY
#71METHODS FOR REGULATING BLOOD-CENTRAL NERVOUS SYSTEM (BLOOD-CNS) BARRIER AND USES THEREOF
#72ASSESSMENT OF INTESTINAL BARRIER FUNCTION TO IMPROVE TREATMENT OF INFLAMMATORY BOWEL DISEASE
#73STABLE AQUEOUS HIGH CONCENTRATION FORMULATION OF INTEGRIN ANTIBODY
#74FUSION PROTEIN WITH IMMUNOENHANCING ACTIVITY
#75Neutralizing antibodies to the αvβ8 integrin complex for immunotherapy
#76Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
#77FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY
#78DOSAGE UNITS AND REGIMEN, USES, METHODS OR FORMULATIONS OF COMPOSITIONS COMPRISING A RECOMBINANT PROTEIN COMPRISING INTERLEUKIN-12 AND AN ANTIBODY BINDING THE EXTRA-DOMAIN B OF FIBRONECTIN
#79IMPLANTABLE CELL CHAMBER DEVICE AND USES THEREOF
#80Antibodies that bind integrin αvβ8 and uses thereof
#81Methods for assessing risk of developing a viral disease using a genetic test
#82ANTIBODIES TO INTEGRIN AVB6 AND USE OF SAME TO TREAT CANCER
#83GENE EDITING METHODS AND COMPOSITIONS FOR ELIMINATING RISK OF JC VIRUS ACTIVATION AND PML (PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY) DURING IMMUNOSUPPRESSIVE THERAPY
#84Treatment Of Kidney Diseases With Angiopoietin Like 3 (ANGPTL3) Inhibitors
#85Treatment Of Lung Conditions With Integrin Subunit Alpha 1 (ITGA1) Inhibitors
#86ANTI-CD103 ANTIBODIES
#87PROCESS FOR PREPARING PURIFIED DRUG CONJUGATES
#88Prevention and treatment of bone and cartilage damage or disease
#89ANTI-avB8 INTEGRIN ANTIBODIES FOR USE IN TREATING KIDNEY DISEASE
#90ALPHA4BETA7 INHIBITOR AND IL-23 INHIBITOR COMBINATION THERAPY
#91CLAUDIN 18.2 ANTIBODY AND USE THEREOF
#92INJECTABLE HIGH CONCENTRATION PHARMACEUTICAL FORMULATIONS AND METHODS OF MANUFACTURING AND USE THEREOF
#93METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
#94FUSION ANTIBODY FOR PRESENTING ANTIGEN-DERIVED T CELL ANTIGEN EPITOPE OR PEPTIDE CONTAINING SAME ON CELL SURFACE, AND COMPOSITION COMPRISING SAME
#95ANTI-INTEGRIN ALPHA-11 MONOCLONAL ANTIBODY AND USE THEREOF
#96METHODS FOR THE TREATMENT OF CHRONIC POUCHITIS
#97TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN INTEGRIN INHIBITOR
#98TREATMENT OF NEUROINFLAMMATORY DISEASE
#99INTEGRIN BETA7 ANTAGONISTS AND METHODS OF TREATING CROHN'S DISEASE
#100METHODS OF ADMINISTERING BETA7 INTEGRIN ANTAGONISTS
#101FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY
#102PREDICTING A TREATMENT RESPONSE IN INFLAMMATORY BOWEL DISEASE
#103USE OF BIOMARKERS FOR ASSESSING TREATMENT OF GASTROINTESTINAL INFLAMMATORY DISORDERS WITH BETA7 INTEGRIN ANTAGONISTS
#104USE OF BIOMARKERS FOR ASSESSING TREATMENT OF GASTROINTESTINAL INFLAMMATORY DISORDERS WITH BETA7 INTEGRIN ANTAGONISTS
#105Pharmaceutical composition for treatment and prevention of chronic disease
#106Copper supplementation for control of glycosylation in mammalian cell culture process
#107ANTI-AVBETA8 ANTIBODIES AND COMPOSITIONS AND USES THEREOF
#108METHODS OF PRODUCING AN ANTI-a4B7 ANTIBODY
#109CELL CULTURE METHODS AND COMPOSITIONS FOR ANTIBODY PRODUCTION
#110METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS
#111INTEGRIN ALPHA10 AND AGGRESSIVE CANCER FORMS
#112ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
#113Antibodies to MAdCAM
#114COMPOSITIONS AND METHODS FOR TREATING NECROTIZING ENTEROCOLITIS
#115ANTIBODY
#116Treatment of cancer with dual targeting of CD47 and EGFR
#117METHODS OF DETECTING MARKERS FOR INFLAMMATORY CONDITIONS AND FOOD SENSITIVITY IN COMPANION ANIMALS
#118Anti-alpha-4-beta-7 antibodies
#119Targeting intraepithelial lymphocytes for treatment of metabolic syndrome
#120STABLE FORMULATIONS OF THERAPEUTIC ANTIBODY
#121Anti-VLA-4 antibodies
#122METHOD OF TREATING PRIMARY SCLEROSING CHOLANGITIS
#123METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST
#124GENERATION OF BRAIN AND SPINAL CORD NEURONS, CARDIAC MYOCYTES, AND HEPATOCYTES USING REG PEPTIDES, PEPTIDOMIMETICS, SMALL MOLECULES AND STIMULATORY ANTIBODIES TO REG RECEPTOR
#125Treatment with anti-α4β7 antibody
#126ANTIBODIES TO INTEGRIN AVB6 AND USE OF SAME TO TREAT CANCER
#127Stable Aqueous Formulations of Natalizumab
#128IMMUNOGLOBULIN FORMULATION AND METHOD OF PREPARATION THEREOF
#129COMPOSITIONS AND METHODS OF ALLEVIATING RESISTANCE TO CHEMOTHERAPY
#130Antibodies that bind integrin AVB8 and uses thereof
#131DETERMINING RESPONDERS TO INFLAMMATION TREATMENT
#132Stable antibody formulation
#133BTNL3/8 targeting constructs for delivery of payloads
#134METHODS OF ADMINISTERING BETA7 INTEGRIN ANTAGONISTS
#135Neutralizing antibodies to the alpha v beta 8 integrin complex for immunotherapy
#136Anti-AVB6 antibodies and antibody-drug conjugates
#137EXTENDED INTERVAL DOSING OF NATALIZUMAB
#138Antibody formulation
#139METHODS AND MATERIALS FOR TREATING GRAFT-VERSUS-HOST DISEASE
#140ANTI-CD40 ANTIBODIES IN COMBINATION AND METHODS OF USE
#141TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNE MODULATORY AGENT RELEASED USING AN INGESTIBLE DEVICE
#142Liquid Protein Formulations Containing Viscosity-Lowering Agents
#143THERAPEUTIC CD47 ANTIBODIES
#144Methods for treatment using anti-alpha4beta7 antibody
#145ANTIBODY AGAINST ALPHA-11 INTEGRIN AND ITS USE
#146Liquid protein formulations containing cyclic adenosine monophosphate (cAMP) or adenosine triphosphate (ATP)
#147Liquid protein formulations containing 4-ethyl-4-methylmorpholinium methylcarbonate (EMMC)
#148Methods and products for evaluating an immune response to a therapeutic protein
#149Methods and compositions relating to bispecific anti-CHI3L1 antibody reagents for the treatment of cancer
#150METHODS AND COMPOSITIONS FOR TREATING NATALIZUMAB-ASSOCIATED PROGRESSIVE MULTIFOCAL ENCEPHALOPATHY
#151INTEGRIN BETA7 ANTAGONISTS AND METHODS OF TREATING CROHN'S DISEASE
#152Methods of Managing Hepatic Steatosis
#153Antibody
#154Formulation for anti-α4β7 antibody
#155TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR
#156Methods of Controlling the Formation of Disulfide Bonds in Protein Solutions
#157Methods and compositions for diagnosing and treating diseases
#158ANTIBODY
#159TUMOUR-TARGETING PEPTIDE VARIANTS
#160ALPHA-V BETA-8 ANTIBODIES
#161Materials and Methods for Eliciting Targeted Antibody Responses In Vivo
#162TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN INTEGRIN INHIBITOR
#163Methods and compositions for treating and preventing disease associated with alpha-v beta-8 integrin
#164Methods of treating patients afflicted with irritable bowel syndrome, inflammatory bowel disease or chronic gastrointestinal functional disorders based on assessment of intestinal barrier function
#165Methods of treating ulcerative colitis
#166Treatment of a disease of the gastrointestinal tract with a SMAD7 inhibitor
#167Biomarkers for assessing the response status for treatment of Inflammatory condition or disease affecting the digestive tract such as inflammatory bowel disease in human patients
#168Methods of treating inflammatory and autoimmune diseases with natalizumab
#169Predicting outcome of treatment with an anti-α4β7 integrin antibody
#170Administration of agents for the treatment of inflammation
#171Immunoparticles and methods of generating and using same
#172FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTIBODY THERAPEUTICS
#173PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF CHRONIC DISEASE
#174METHODS FOR THE TREATMENT OF CHRONIC POUCHITIS
#175Anti-AVB8 antibodies and compositions and uses thereof
#176HUMANIZED ANTI-BETA7 ANTAGONISTS AND USES THEREFOR
#177Treatment of cancer with anti-LAP monoclonal antibodies
#178Prevention and treatment of bone and cartilage damage or disease
#179ANTIBODIES TO INTEGRIN AVB6 AND USE OF SAME TO TREAT CANCER
#180Vedolizumab for the treatment of fistulizing Crohn's disease
#181USE OF BIOMARKERS FOR ASSESSING TREATMENT OF GASTROINTESTINAL INFLAMMATORY DISORDERS WITH BETA7 INTEGRIN ANTAGONISTS
#182Disintegrin variants and pharmaceutical uses thereof
#183Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
#184METHOD OF ADMINISTERING AN ANTIBODY
#185METHOD OF PREVENTING GRAFT VERSUS HOST DISEASE
#186METHOD OF TREATING AND DIAGNOSING ALPHA-V-BETA-6 OVEREXPRESSING CANCER
#187Methods for assessing risk of developing a viral disease using a genetic test
#188Methods for assessing risk of developing a viral disease using a genetic test
#189Anti-VLA-4 antibodies
#190CD47-CAR-T cells
#191PHARMACEUTICAL ASSOCIATION OF GROWTH FACTOR RECEPTOR AGONIST AND ADHESION PROTEIN INHIBITOR FOR CONVERTING A NEOPLASTIC CELL INTO A NON-NEOPLASTIC CELL AND USES THEREOF
#192GENERATION OF BRAIN AND SPINAL CORD NEURONS, CARDIAC MYOCYTES, RENAL NEPHRONS AND HEPATOCYTES USING REG PEPTIDES, PEPTIDOMIMETICS, SMALL MOLECULES AND STIMULATORY ANTIBODIES TO REG RECEPTOR
#193Treatment of cancer with dual targeting of CD47 and EGFR
#194Cyclic RGD cell-binding motif and uses thereof
#195Methods of treating inflammatory and autoimmune diseases with natalizumab
#196USE OF BIOMARKERS FOR ASSESSING TREATMENT OF GASTROINTESTINAL INFLAMMATORY DISORDERS WITH BETA7 INTEGRIN ANTAGONISTS
#197MODIFIED ANTIGEN-BINDING FAB FRAGMENTS AND ANTIGEN-BINDING MOLECULES COMPRISING THE SAME
#198ANTI-ITGA3 ANTIBODIES, ACTIVATABLE ANTI-ITGA3 ANTIBODIES, AND METHODS OF USE THEREOF
#199Therapeutic CD47 antibodies
#200PHARMACEUTICAL ASSOCIATION OF GROWTH FACTOR RECEPTOR AGONIST AND ADHESION PROTEIN INHIBITOR FOR CONVERTING A NEOPLASTIC CELL INTO A NON-NEOPLASTIC CELL AND USES THEREOF
#201Integrin alpha 9 blockade suppresses lymphatic valve formation and promotes transplant survival
#202ANTI-ALPHA-V INTEGRIN ANTIBODY FOR THE TREATMENT OF PROSTATE CANCER
#203Methods for diagnosing and treating inflammatory bowel disease
#204Method of treating inflammatory bowel disease
#205Gene editing methods and compositions for eliminating risk of JC virus activation and PML (progressive multifocal leukoencephalopathy) during immunosuppressive therapy
#206FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY AND METHODS OF TREATMENT
#207Neutralizing antibodies to the αvβ8 integrin complex for immunotherapy
#208USE OF AN ANTI-PD-1 ANTIBODY IN COMBINATION WITH AN ANTI-MESOTHELIN ANTIBODY IN CANCER TREATMENT
#209Hemostatic material, preparation method thereof and pharmaceutical composition containing the same
#210Targeting the cofilin pathway
#211Methods of Treating Sickle Cell Disease
#212Generating targeted sequence diversity in fusion proteins
#213Methods of using anti-lap antibodies
#214BK VIRUS SEROLOGY ASSESSMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) RISK
#215METHODS OF TREATING OR PREVENTING GRAFT VERSUS HOST DISEASE
#216FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY
#217Methods and compositions relating to anti-CHI3L1 antibody reagents to treat cancer
#218Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment
#219Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
#220Method of identifying a status of a mucosal intestinal epithelial barrier to improve treatment of inflammatory bowel disease
#221Process for preparing purified drug conjugates
#222METHODS AND COMPOSITIONS USING INTEGRIN-BASED THERAPEUTICS
#223FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY
#224TREATMENT OF NEUROINFLAMMATORY DISEASE
#225Methods for diagnosing and treating inflammatory bowel disease
#226MILK FAT GLOBULE EPIDERMAL GROWTH FACTOR 8 REGULATES FATTY ACID UPTAKE
#227Methods of detecting markers for inflammatory conditions and food sensitivity in companion animals
#228FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY
#229ANTI-CD40 ANTIBODIES IN COMBINATION AND METHODS OF USE
#230A METHOD OF INHIBITING EXACERBATIONS OF T CELL-MEDIATED ALLOGRAFT VASCULOPATHY
#231Methods of detecting markers for inflammatory conditions and food sensitivity in companion animals
#232HUMANIZED ANTI-BETA7 ANTAGONISTS AND USES THEREFOR
#233METHODS OF TREATING INFLAMMATORY BOWEL DISEASE
#234Antibody for immunoassay and method for preparing same
#235METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING DISEASES
#236Methods and compositions for treating and preventing disease associated with alpha-v beta-8 integrin
#237Antibody
#238Materials and Methods for Eliciting Targeted Antibody Responses In Vivo
#239Methods for assessing risk of developing a viral disease using a genetic test
#240Anti-VLA-4 antibodies
#241METHODS OF TREATING ULCERATIVE COLITIS
#242Immunoglobulin formulation and method of preparation thereof
#243Liquid Protein Formulations Containing Thiamine
#244Liquid protein formulations containing cimetidine
#245Method for treatment or prevention of a cancer
#246Method of Increasing GIPCR Signalization in the Cells of a Scoliotic Subject
#247Therapeutic CD47 antibodies
#248Cyclic RGD cell-binding motif and uses thereof
#249Liquid protein formulations containing thiamine pyrophosphate (TPP)
#250Methods for Treating Corneal and Conjunctival Inflammation and Inflammatory Disorders
#251Gene editing methods and compositions for eliminating risk of JC virus activation and PML (progressive multifocal leukoencephalopathy) during immunosuppressive therapy
#252Generating targeted sequence diversity in fusion proteins
#253Methods and products for evaluating an immune response to a therapeutic protein
#254INTEGRIN BETA7 ANTAGONISTS AND METHODS OF TREATING CROHN'S DISEASE
#255Liquid protein formulations containing 4-(3-butyl-1-imidazolio)-1-butane sulfonate (BIM)
#256METHOD OF TREATING PRIMARY SCLEROSING CHOLANGITIS
#257Treatment of cancer with anti-lap monoclonal antibodies
#258Methods and compositions related to modulators of eukaryotic cells
#259Method of treating cancer with a multiple integrin binding Fc fusion protein
#260HUMANIZED ANTI-ALPHA V BETA 5 ANTIBODIES AND USES THEREOF
#261PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-alpha4beta7 INTEGRIN ANTIBODY
#262Detection of activated monocytes in human peripheral blood and determining the concentration of cell surface integrin using plasmon amplified raman detection
#263Copper supplementation for control of glycosylation in mammalian cell culture process
#264Hypotaurine, GABA, Beta-Alanine, and Choline for Control of Waste Byproduct Accumulation in Mammalian Cell Culture Process
#265Vedolizumab for the Treatment of Fistulizing Crohn's Disease
#266ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
#267Multivalent and monovalent multispecific complexes and their uses
#268ALPHA-4-BETA-7 HETERODIMER SPECIFIC ANTAGONIST ANTIBODY
#269Production of proteins in labyrinthulomycetes
#270Methods of treating inflammatory and autoimmune diseases with natalizumab
#271Methods for diagnosing and treating inflammatory bowel disease
#272ANTI-ALPHA-V INTEGRIN ANTIBODY FOR THE TREATMENT OF PROSTATE CANCER
#273HUMANIZED ANTI-BETA7 ANTAGONISTS AND USES THEREFOR
#274Treatment of cancer with dual targeting of CD47 and EGFR
#275SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND COMBINATION THERAPY THEREWITH
#276ALPHA-V BETA-8 ANTIBODIES
#277Compositions and methods to treat solid tumors
#278USE OF BIOMARKERS FOR ASSESSING TREATMENT OF GASTROINTESTINAL INFLAMMATORY DISORDERS WITH BETA7 INTEGRIN ANTAGONISTS
#279Targeted coagulation factors and method of using the same
#280HUMANIZED ANTI-BETA7 ANTAGONISTS AND USES THEREFOR
#281METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
#282Methods of treating ulcerative colitis
#283COMBINATION TREATMENT FOR MULTIPLE SCLEROSIS
#284ANTIBODIES TO INTEGRIN AVB6 AND USE OF SAME TO TREAT CANCER
#285ALPHA-V BETA-6 INTEGRIN-BINDING ANTIBODY FRAGMENTS
#286A METHOD OF INCREASING GIPCR SIGNALIZATION IN THE CELLS OF A SCOLIOTIC SUBJECT
#287Methods of Treating and Preventing Minor Histocompatibility Antigen-Mismatched Grafts
#288Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof
#289Molecular constructs for treating central nervous system diseases
#290Formulation for anti-α4β7 antibody
#291Methods of treating ulcerative colitis
#292Molecular constructs for treating infectious diseases
#293Molecular constructs with targeting and effector moieties for treating infectious diseases
#294Molecular constructs with targeting and effector moieties comprising an SCFV specific for ectodomain of transferrin-1 receptor and fingolimod
#295Peptide core-based multi-arm linkers for treating infectious diseases
#296Peptide core-based multi-arm linkers for treating central nervous system diseases
#297Peptide core-based multi-arm linkers and their applications
#298Use of antagonists of the interaction between HIV GP120 and α4β7 integrin
#299METHODS OF TREATING AND DIAGNOSING ALPHA-V-BETA-6 OVEREXPRESSING CANCER
#300Monoclonal antibody capable of binding integrin alpha 10 beta 1